Rapid Disease Progression of Advanced Non-small Cell Lung Cancer Five Months after Cessation of Pembrolizumab

Atsuko Hirabae; Eiki Ichihara; Ryota Sunami; Moeko Ota; Yoshitaka Iwamoto; Yoshinobu Maeda; Katsuyuki Kiura

Rapid Disease Progression of Advanced Non-small Cell Lung Cancer Five Months after Cessation of Pembrolizumab

Atsuko Hirabae, Eiki Ichihara, Ryota Sunami, Moeko Ota, Yoshitaka Iwamoto, Yoshinobu Maeda, Katsuyuki Kiura

Research output: Contribution to journal › Article › peer-review

Abstract

We report a case of late-onset hyperprogressive disease after cessation of a PD-1 inhibitor. A male was diagnosed with metastatic lung adenocarcinoma with little progression for 2 months before treatment. He received pembrolizumab as a second-line treatment and was subsequently prescribed docetaxel for 3 months until a slight increase in pleural effusion. At the time of progression to docetaxel, he commenced prednisolone because of immune-system-related diarrhea. After that, his general condition rapidly worsened with severe fatigue and hypoxia. Computed tomography revealed a massive increase of pleural effusion and replacement of almost the entire liver with cancer over a period of 5 weeks.

Original language	English
Pages (from-to)	423-425
Number of pages	3
Journal	Acta medica Okayama
Volume	74
Issue number	5
Publication status	Published - 2020

Keywords

hyperprogression
immune checkpoint inhibitors
lung cancer
pembrolizumab

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{f8e9028338254c0db3ffbc22a96df60f,

title = "Rapid Disease Progression of Advanced Non-small Cell Lung Cancer Five Months after Cessation of Pembrolizumab",

abstract = "We report a case of late-onset hyperprogressive disease after cessation of a PD-1 inhibitor. A male was diagnosed with metastatic lung adenocarcinoma with little progression for 2 months before treatment. He received pembrolizumab as a second-line treatment and was subsequently prescribed docetaxel for 3 months until a slight increase in pleural effusion. At the time of progression to docetaxel, he commenced prednisolone because of immune-system-related diarrhea. After that, his general condition rapidly worsened with severe fatigue and hypoxia. Computed tomography revealed a massive increase of pleural effusion and replacement of almost the entire liver with cancer over a period of 5 weeks.",

keywords = "hyperprogression, immune checkpoint inhibitors, lung cancer, pembrolizumab",

author = "Atsuko Hirabae and Eiki Ichihara and Ryota Sunami and Moeko Ota and Yoshitaka Iwamoto and Yoshinobu Maeda and Katsuyuki Kiura",

note = "Publisher Copyright: Copyright{\textcopyright} 2020 by Okayama University Medical School.",

year = "2020",

language = "English",

volume = "74",

pages = "423--425",

journal = "Acta Medica Okayama",

issn = "0386-300X",

publisher = "Okayama University",

number = "5",

}

TY - JOUR

T1 - Rapid Disease Progression of Advanced Non-small Cell Lung Cancer Five Months after Cessation of Pembrolizumab

AU - Hirabae, Atsuko

AU - Ichihara, Eiki

AU - Sunami, Ryota

AU - Ota, Moeko

AU - Iwamoto, Yoshitaka

AU - Maeda, Yoshinobu

AU - Kiura, Katsuyuki

PY - 2020

Y1 - 2020

N2 - We report a case of late-onset hyperprogressive disease after cessation of a PD-1 inhibitor. A male was diagnosed with metastatic lung adenocarcinoma with little progression for 2 months before treatment. He received pembrolizumab as a second-line treatment and was subsequently prescribed docetaxel for 3 months until a slight increase in pleural effusion. At the time of progression to docetaxel, he commenced prednisolone because of immune-system-related diarrhea. After that, his general condition rapidly worsened with severe fatigue and hypoxia. Computed tomography revealed a massive increase of pleural effusion and replacement of almost the entire liver with cancer over a period of 5 weeks.

AB - We report a case of late-onset hyperprogressive disease after cessation of a PD-1 inhibitor. A male was diagnosed with metastatic lung adenocarcinoma with little progression for 2 months before treatment. He received pembrolizumab as a second-line treatment and was subsequently prescribed docetaxel for 3 months until a slight increase in pleural effusion. At the time of progression to docetaxel, he commenced prednisolone because of immune-system-related diarrhea. After that, his general condition rapidly worsened with severe fatigue and hypoxia. Computed tomography revealed a massive increase of pleural effusion and replacement of almost the entire liver with cancer over a period of 5 weeks.

KW - hyperprogression

KW - immune checkpoint inhibitors

KW - lung cancer

KW - pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=85094845263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85094845263&partnerID=8YFLogxK

M3 - Article

C2 - 33106698

AN - SCOPUS:85094845263

SN - 0386-300X

VL - 74

SP - 423

EP - 425

JO - Acta Medica Okayama

JF - Acta Medica Okayama

IS - 5

ER -

Rapid Disease Progression of Advanced Non-small Cell Lung Cancer Five Months after Cessation of Pembrolizumab

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this